Status:
COMPLETED
Iodinated Contrast Media Induced Hyperthyroidism
Lead Sponsor:
Medical University of Warsaw
Collaborating Sponsors:
National Institute of Cardiology, Warsaw, Poland
Conditions:
Hyperthyroidism/Thyrotoxicosis
Hyperthyroidism; Goiter
Eligibility:
All Genders
18+ years
Brief Summary
The proper synthesis of thyroid hormones is dependent on adequate iodine supply. The mean daily iodine intake recommended by World Health Organization is 150 mg. Iodinated contrast medium (ICM) typica...
Detailed Description
Patients were divided into two subsets on the basis of received prophylactic therapy. Group with prophylaxis (13 patients) received thiamazole alone (7 patients) or with sodium perchlorate (6 patients...
Eligibility Criteria
Inclusion
- euthyroidism at baseline (defined as TSH level within the reference range)
- diffuse or multinodular goiter
- iodinated contrast media (ICM) exposure
- time of observation after ICM exposure longer than 4 weeks
Exclusion
- Graves' disease
- administration of thyroid hormones, glucocorticoids, iodine-containing medications or iodine contrast agent within the past 6 months
Key Trial Info
Start Date :
January 2 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 20 2020
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT04304794
Start Date
January 2 2015
End Date
February 20 2020
Last Update
March 11 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.